XML 57 R19.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes
12 Months Ended
Dec. 31, 2019
Income Taxes [Abstract]  
Income Taxes
Note 13 – Income Taxes

A reconciliation of the statutory U.S. federal income tax rate to the Company’s effective tax rate is as follows:

  
Year Ended December 31,
 
  
2019
  
2018
 
Federal statutory rate
  
21.0
%
  
21.0
%
State taxes
  
21.1
%
  
5.4
%
Extraordinary Gain
  
38.0
%
  
 
Permanent differences
  
(4.1
)%
  
(1.8
)%
Research and development
  
4.1
%
  
0.2
%
Valuation allowance
  
(74.6
)%
  
(24.8
)%
Other
  
(0.3
)%
  
 
Effective tax rate
  
5.2
%
  
 

The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows:

  
December 31,
 
  
2019
  
2018
 
Federal net operating losses
 
$
16,620,765
  
$
5,147,280
 
State net operating losses
  
4,653,462
   
 
Stock options
  
2,153,487
   
 
Warrants
  
143,841
   
 
Federal tax credit
  
740,040
   
 
State tax credits
  
657,376
   
 
Amortization
  
47,811
   
2,238
 
Accrued expense
  
363,617
   
 
Depreciation
  
719,263
   
438
 
In-process R&D
  
   
98,427
 
Other
  
18,098
   
 
Total gross deferred tax assets
  
26,117,760
   
5,248,383
 
Less valuation allowance
  
(26,117,760
)
  
(5,248,383
)
Net deferred tax assets
 
$
  
$
 

In assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and negative evidence to determine whether it is more likely than not that some portion of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. At December 31, 2019 and 2018, the Company has recorded a full valuation allowance against its net deferred tax assets of approximately $26.1 and $5.2 million respectively. The change in the valuation allowance during the year ended 2019 was approximately $20.8 million.

At December 31, 2019, the Company had federal net operating loss (“NOL”) carryforwards of approximately $79.1 million. At December 31, 2019, the Company had federal research and development credit carryforwards of approximately $0.7 million. The federal net operating loss carryforwards begin to expire in 2028, losses generated in 2018 or later will carry forward indefinitely. The federal credit carryforwards begin to expire in 2032. Section 382 and 383 of the Internal Revenue Code of 1986 subject the future utilization of net operating losses and certain other tax attributes, such as research and experimental tax credits, to an annual limitation in the event certain ownership changes, as defined. The Company may be subject to the net operating loss utilization provisions of Section 382 of the Internal Revenue Code.  The effect of an ownership change would be the imposition of an annual limitation on the use of NOL carryforwards attributable to periods before the change.  The amount of the annual limitation depends upon the value of the Company immediately before the change, changes to the Company’s capital during a specified period prior to the change, and the federal published interest rate.  Although the Company has not completed an analysis under Section 382 of the Code, it is likely that the utilization of the NOLs will be limited

At December 31, 2019, the Company had approximately $65.4 million of State of New Jersey NOLs which expire between 2029 and 2039. At December 31, 2019, the Company had approximately $0.8 million of the State of New Jersey research development credits carryforwards.  The State of New Jersey has enacted legislation permitting certain corporations located in New Jersey to sell state tax loss carryforwards and state research and development credits, or net loss carryforwards. The Technology Business Tax Certificate Transfer Program enables qualified, unprofitable NJ-based technology or biotechnology companies with fewer than 225 US employees (including parent company and all subsidiaries) to sell a percentage of New Jersey NOLs and research and development (“R&D”) tax credits to unrelated profitable corporations.  In 2019, the Company did not qualify for the program. There is no certainty as to whether this program will continue.

Entities are also required to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of December 31, 2019, there were no uncertain positions. The Company’s U.S. federal and state net operating losses have occurred since its inception in 2009 and as such, tax years subject to potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities. Interest and penalties, if any, as they relate to income taxes assessed, are included in the income tax provision. The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties for the years ended December 31, 2019 and 2018.